Atypical Hemolytic and Uremic Syndrome Triggered by Infection With SARS-CoV2
Jessica Kaufeld, Martin Reinhardt, Christoph Schröder, Jan Hinrich Bräsen, Thorsten Wiech, Philipp Brylka, Akel Khaled, Carsten Bergmann, Hermann Haller, Anja Gäckler, Bernhard Magnus Wilhelm Schmidt
Abstract
Atypical hemolytic and uremic syndrome (aHUS), as a form of thrombotic microangiopathy, (TMA) is characterized by a genetic or acquired dysregulation of complement activation, leading to endothelial cell lesions and thrombosis of the small vessels, hemolysis, thrombocytopenia, and acute kidney injury.S1 Here, we report 2 cases of complement mediated aHUS triggered by infection with SARS-CoV-2.
Topics & Concepts
Thrombotic microangiopathyAtypical hemolytic uremic syndromeMedicineEculizumabComplement systemHemolysisImmunologyAcute kidney injuryThrombosisPathologyInternal medicineAntibodyDiseaseComplement system in diseasesSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies